You are here

Article Text

Article menu
Download PDFPDF
Aetiology
Systematic review and meta-analysis
Need for standardising adverse event reporting in testosterone trials

https://doi.org/10.1136/eb-2013-101402

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Correction notice This article has been corrected since it was published Online First. The competing interests have been amended from ‘None.’ to the current text.

    • Competing interests The author has declared prior financial activities outside the submitted work, relationships during the past 36 months with Eli Lilly, and Abbvie and Clarus Pharmaceuticals. The Editor notes that The Endocrine Society reported a study led by Dr. Basaria in 2013 supported by Abbott Pharmaceuticals (http://edrv.endojournals.org/cgi/content/meeting_abstract/34/03_MeetingAbstracts/LB-FP-6) and theheart.org published that Dr. Basaria reports financial relationships with Novartis, GlaxoSmithKline, Solvay Pharmaceuticals, Merck and Ligand Pharmaceuticals http://www.theheart.org/article/1094777/print.do). His study in the N Engl J Med was supported in part by Auxilium Pharmaceuticals (DOI: 10.1056/NEJMoa1000485).